Moderna - Search News

FDA approves Moderna's mRNA flu vaccine

FDA approves Moderna's mRNA flu vaccine after initial pushback

The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.

· 21h · on MSN

FDA approves first mRNA flu vaccine in win for Moderna after arduous review

· 1d

FDA approves Moderna's mRNA flu vaccine after initially refusing to review it

· 1d

US FDA approves first mRNA flu shot from Moderna

The U.S. Food and Drug Administration has approved Moderna's (MRNA.O) flu vaccine for people aged 50 and older, the company said on Wednesday, marking the first approval of a messenger RNA-based vacci...

· 12h

Moderna's mRNA flu vaccine gets approved after rare FDA refusal to review. What changed?

· 1d

FDA approves first mRNA-based flu vaccine

· 1d

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA

“The FDA approval of mFLUSIVA, our fourth approved product in the United States and the first mRNA-based flu vaccine, demonstrates the continued strength and versatility of our mRNA platform,” said St...

· 14h

FDA approves first mRNA vaccine for seasonal flu

· 1d

FDA Approves First mRNA Flu Vaccine in Win for Moderna After Arduous Review

Medindia

Moderna Begins World's First Human Trial for Bundibugyo Ebola Vaccine

Moderna has launched the world's first Phase 1 trial of a Bundibugyo Ebola mRNA vaccine, targeting an Ebola strain that still has no approved vaccine.

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines

16h

Moderna Stock Flashing Intriguing ‘Buy The Dip’ Signal

Drug stock Moderna (MRNA) is pulling back to a historically bullish trendline and has plenty of contrarian signals flashing

22hon MSN

Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future

Moderna’s mRNA-based flu vaccine, mFlusiva, is approved by the Food and Drug Administration for adults aged 50 and over.